
HCPLive 5 Stories in Under 5: Week of 08/10
Key Takeaways
- FDA approval of generic iron sucrose injections increases treatment options for iron deficiency anemia in CKD patients.
- PharmaTher's ketamine formulation gains FDA approval for surgical pain management after resolving application deficiencies.
An audio recap of the top 5 stories in healthcare news from the week of 08/10-08/16.
Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!
Interested in a more traditional, text rundown?
Top 5 Healthcare Headlines for August 10-16, 2025:
The FDA approved 2 generic versions of iron sucrose injection for treating iron deficiency anemia in patients with CKD, expanding access to therapy.
The FDA approved PharmaTher’s ketamine formulation for surgical pain management following resolution of earlier application deficiencies.
The HFSA and ASPC issued a joint statement urging clinicians to prioritize prevention and early risk management in heart failure care.
The FDA approved zopapogene imadenovec as the first immunotherapy for recurrent respiratory papillomatosis, offering a new treatment option.
The AHA and ACC released updated hypertension guidelines recommending earlier intervention to lower cardiovascular disease risk.















































































